News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
The drug discovery and development services organization added four to its senior leadership team: David Hedden, PhD, as chief scientific officer, Brett Truitt, MS, MBA, as vice president, cGMP operations, Mohan Thiruvazhi, PhD, as vice president, business development, and Raymond Li, CPA, MBA, as vice president, finance.
Hedden, with 32 years of industry experience, will lead the formulation and analytical development team. He has worked at Pfizer, UPM, Ironwood, Searle/Pharmacia, Sandoz, Dupont, and Adagio.
Truitt joins BioDuro from Patheon where he was the director of pharmaceutics and process technology. He has 20 years of experience and has held roles at Flatley Discovery Labs, Shire, Pfizer, Proctor and Gamble, among other companies.
In his new role, Thiruvazhi will be responsible for global business development efforts in North America, South America, and Europe. He previously worked at GVK BIO and Syngene International and ran chemistry operations for six years at ChemBridge Research Labs.
Li was most recently the vice president of finance and operations at Amrx. He has held senior positions at publicly traded, fortune 500 companies, including K2 and Emerson Electric.